HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras.

AbstractBACKGROUND:
The aim of this study was to analyze the survival difference between advanced non-small cell lung cancer (NSCLC) patients in the pre-gefitinib and post-gefitinib eras in Korea.
PATIENTS AND METHODS:
830 patients with advanced/metastatic or recurrent NSCLC who received palliative chemotherapy were retrospectively reviewed. Using a matched-pair case-control study design, 334 pairs from the pre-gefitinib era (January 1999 to December 2001) and the post-gefitinib era (January 2002 to December 2005) were matched by age, sex and histology.
RESULTS:
The median overall survival from the date of first administration of palliative chemotherapy was significantly longer in the post-gefitinib era (11.5 vs. 19.3 months, p< 0.001). Multivariate analysis showed that gefitinib was associated with longer overall survival (hazard ratio 0.58, p< 0.001) as were never having been a smoker, adenocarcinoma histology, good performance, stage IIIB, >or=3 prior episodes of chemotherapy, platinum-based chemotherapy and previous docetaxel or pemetrexed treatment. Patients in the post-gefitinib era showed significantly longer overall survival in almost all subgroups. Gefitinib treatment was of significantly greater benefit in patients with adenocarcinoma than in those with non-adenocarcinoma (test for interaction p< 0.001).
CONCLUSION:
These results indicate a significant improvement of survival in advanced NSCLC patients treated with gefitinib in Korea.
AuthorsHyo Song Kim, Keunchil Park, Hyun Jung Jun, Seong Yoon Yi, Jeeyun Lee, Jin Seok Ahn, Yeon Hee Park, Seonwoo Kim, Sangcheol Lee, Myung-Ju Ahn
JournalOncology (Oncology) Vol. 76 Issue 4 Pg. 239-46 ( 2009) ISSN: 1423-0232 [Electronic] Switzerland
PMID19246948 (Publication Type: Comparative Study, Journal Article)
CopyrightCopyright 2009 S. Karger AG, Basel.
Chemical References
  • Antineoplastic Agents
  • Quinazolines
  • ErbB Receptors
  • Gefitinib
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents (therapeutic use)
  • Carcinoma, Non-Small-Cell Lung (drug therapy, mortality)
  • Case-Control Studies
  • ErbB Receptors (antagonists & inhibitors)
  • Female
  • Gefitinib
  • Humans
  • Lung Neoplasms (drug therapy, mortality)
  • Male
  • Middle Aged
  • Quinazolines (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: